How to buy Verve Therapeutics IncCommon Stock stock | $43.93

Verve Therapeutics Inc. Common Stock is a biotechnology business based in the US. Verve Therapeutics IncCommon Stock shares (VERV) are listed on the NASDAQ and all prices are listed in US Dollars.

Verve Therapeutics IncCommon Stock stock price (NASDAQ: VERV)

Use our graph to track the performance of VERV stocks over time.

Verve Therapeutics IncCommon Stock shares at a glance

• Key figures

Information last updated 2021-10-10.

Latest market close	$43.93
52-week range	$29.50 - $78.00
50-day moving average	$59.35
200-day moving average	$55.86
Wall St. target price	$72.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-25.50

Buy Verve Therapeutics IncCommon Stock shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Verve Therapeutics IncCommon Stock stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Verve Therapeutics IncCommon Stock price performance over time

Historical closes compared with the close of $43.93 from 2021-10-15

1 week (2021-10-08)	-0.02%
1 month (2021-09-16)	-37.13%
3 months (2021-07-16)	-9.55%
6 months (2021-04-12)	N/A

1 year (2020-10-12)	N/A
2 years (2019-10-12)	N/A
3 years (2018-10-12)	N/A
5 years (2016-10-12)	N/A

Verve Therapeutics IncCommon Stock financials

Gross profit TTM	$0
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	$8.46
Market capitalisation	$2.1 billion

TTM: trailing 12 months

Shorting Verve Therapeutics IncCommon Stock shares

There are currently 1.9 million Verve Therapeutics IncCommon Stock shares held short by investors – that's known as Verve Therapeutics IncCommon Stock's "short interest". This figure is 1.5% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting Verve Therapeutics IncCommon Stock shares can be evaluated.

Verve Therapeutics IncCommon Stock's "short interest ratio" (SIR)

Verve Therapeutics IncCommon Stock's "short interest ratio" (SIR) is the quantity of Verve Therapeutics IncCommon Stock shares currently shorted divided by the average quantity of Verve Therapeutics IncCommon Stock shares traded daily (recently around 311422.27722772). Verve Therapeutics IncCommon Stock's SIR currently stands at 6.06. In other words for every 100,000 Verve Therapeutics IncCommon Stock shares traded daily on the market, roughly 6060 shares are currently held short.

To gain some more context, you can compare Verve Therapeutics IncCommon Stock's short interest ratio against those of similar companies.

• Stealth BioTherapeutics (MITO.US): 1.54
• Annexon (ANNX.US): 8.13
• Axsome Therapeutics (AXSM.US): 1.86

However Verve Therapeutics IncCommon Stock's short interest can also be evaluated against the total number of Verve Therapeutics IncCommon Stock shares, or, against the total number of tradable Verve Therapeutics IncCommon Stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verve Therapeutics IncCommon Stock's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Verve Therapeutics IncCommon Stock shares in existence, roughly 40 shares are currently held short) or 0.0722% of the tradable shares (for every 100,000 tradable Verve Therapeutics IncCommon Stock shares, roughly 72 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Verve Therapeutics IncCommon Stock.

Find out more about how you can short Verve Therapeutics IncCommon Stock stock.

Verve Therapeutics IncCommon Stock share dividends

We're not expecting Verve Therapeutics IncCommon Stock to pay a dividend over the next 12 months.

Verve Therapeutics IncCommon Stock overview

Verve Therapeutics, Inc. , a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc. ; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc.

Frequently asked questions

What percentage of Verve Therapeutics IncCommon Stock is owned by insiders or institutions?
Currently 6.932% of Verve Therapeutics IncCommon Stock shares are held by insiders and 55.823% by institutions. When does the fiscal year end for Verve Therapeutics IncCommon Stock?
Verve Therapeutics IncCommon Stock's fiscal year ends in December. Where is Verve Therapeutics IncCommon Stock based?
Verve Therapeutics IncCommon Stock's address is: 500 Technology Square, Cambridge, MA, United States, 02139 What is Verve Therapeutics IncCommon Stock's ISIN number?
Verve Therapeutics IncCommon Stock's international securities identification number is: US92539P1012